Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DZZZ | ISIN: US1628282063 | Ticker-Symbol: CZTA
Tradegate
21.11.24
18:55 Uhr
3,390 Euro
+0,195
+6,10 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CHECKPOINT THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CHECKPOINT THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,3003,33022:04
3,2303,40022:00

Aktuelle News zur CHECKPOINT THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.11.Checkpoint Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary5
12.11.Checkpoint Therapeutics GAAP EPS of -$0.23 misses by $0.082
12.11.Checkpoint Therapeutics, Inc: Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates157Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint")...
► Artikel lesen
12.11.Checkpoint Therapeutics, Inc. - 8-K, Current Report-
16.09.Checkpoint Therapeutics meldet vielversprechende Ergebnisse der Cosibelimab-Studie20
CHECKPOINT THERAPEUTICS Aktie jetzt für 0€ handeln
16.09.Checkpoint Therapeutics reports promising cosibelimab trial results1
16.09.Checkpoint Therapeutics Presents Cosibelimab Longer-Term Results In Advanced CSCC1
16.09.Checkpoint Therapeutics, Inc: Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 202487WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the presentation...
► Artikel lesen
04.09.Checkpoint Therapeutics, Inc: Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference2
19.08.Checkpoint Therapeutics files secondary offering of up to 5.9M shares6
12.08.Checkpoint Therapeutics GAAP EPS of -$0.18 beats by $0.101
12.08.Checkpoint Therapeutics, Inc. - 10-Q, Quarterly Report1
12.08.Checkpoint Therapeutics, Inc. - 8-K, Current Report1
12.08.Checkpoint Therapeutics, Inc: Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates185WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
► Artikel lesen
25.07.Checkpoint Therapeutics, Inc. - 8-K, Current Report1
25.07.Checkpoint Therapeutics, Inc: Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma338WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the...
► Artikel lesen
15.07.Checkpoint Therapeutics, Inc: GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research7
03.07.Checkpoint Therapeutics, Inc. - 8-K, Current Report1
02.07.Checkpoint Therapeutics looks to raise $12M through direct offering3
02.07.Checkpoint Therapeutics, Inc: Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab118WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has...
► Artikel lesen
Seite:  Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,1